Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin

被引:42
作者
Cameron, Chris [1 ]
Coyle, Doug [2 ]
Ur, Ehud [3 ,4 ]
Klarenbach, Scott [5 ]
机构
[1] CADTH, COMPUS, Ottawa, ON K1S 5S8, Canada
[2] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada
[3] Univ British Columbia, St Pauls Hosp, Div Endocrinol, Vancouver, BC V5Z 1M9, Canada
[4] Univ British Columbia, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada
[5] Univ Alberta, Dept Med, Calgary, AB, Canada
关键词
RANDOMIZED CONTROLLED-TRIAL; UNITED-STATES; ECONOMIC EVALUATIONS; ATRIAL-FIBRILLATION; GLYCEMIC CONTROL; PARALLEL-GROUP; MODEL; RISK; MULTICENTER; EFFICACY;
D O I
10.1503/cmaj.090765
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The benefits of self-monitoring blood glucose levels are unclear in patients with type 2 diabetes mellitus who do not use insulin, but there are considerable costs. We sought to determine the cost effectiveness of self-monitoring for patients with type 2 diabetes not using insulin. Methods: We performed an incremental cost-effectiveness analysis of the self-monitoring of blood glucose in adults with type 2 diabetes not taking insulin. We used the United Kingdom Prospective Diabetes Study (UKPDS) model to forecast diabetes-related complications, corresponding quality-adjusted life years and costs. Clinical data were obtained from a systematic review comparing self-monitoring with no self-monitoring. Costs and utility decrements were derived from published sources. We performed sensitivity analyses to examine the robustness of the results. Results: Based on a clinically modest reduction in hemoglobin A(1C) of 0.25% (95% confidence interval 0.15-0.36) estimated from the systematic review, the UKPDS model predicted that self-monitoring performed 7 or more times per week reduced the lifetime incidence of diabetes-related complications compared with no self-monitoring, albeit at a higher cost (incremental cost per quality-adjusted life year $113 643). The results were largely unchanged in the sensitivity analysis, although the incremental cost per quality-adjusted life year fell within widely cited cost-effectiveness thresholds when testing frequency or the price per test strip was substantially reduced from the current levels. Interpretation: For most patients with type 2 diabetes not using insulin, use of blood glucose test strips for frequent self-monitoring (>= 7 times per week) is unlikely to represent efficient use of finite health care resources, although periodic testing (e.g., 1 or 2 times per week) may be cost-effective. Reduced test strip price would likely also improve cost-effectiveness.
引用
收藏
页码:28 / 34
页数:7
相关论文
共 49 条
[1]  
*AG HEALTHC RES QU, 2005, CALC US POP BAS EQ 5
[2]  
Albert P, 2007, AUSTRALAS I MIN MET, V2007, P7
[3]  
[Anonymous], CAN J DIABETES
[4]  
[Anonymous], DIABETES ONTARIO ICE
[5]   The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study) [J].
Barnett, A. H. ;
Krentz, A. J. ;
Strojek, K. ;
Sieradzki, J. ;
Azizi, F. ;
Embong, M. ;
Imamoglu, S. ;
Perusicova, J. ;
Uliciansky, V. ;
Winkler, G. .
DIABETES OBESITY & METABOLISM, 2008, 10 (12) :1239-1247
[6]  
Berger M.L., 2003, Health care cost, quality
[7]   Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia A nested case-control analysis [J].
Bodmer, Michael ;
Meier, Christian ;
Kraehenbuehl, Stephan ;
Jick, Susan S. ;
Meier, Christoph R. .
DIABETES CARE, 2008, 31 (11) :2086-2091
[8]  
*BROG INC, 2008, UT OR ANT CAN UNPUB
[9]  
CADTH, 2017, Guidelines for the Economic Evaluation of Health Technologies: Canada
[10]  
CAMERON C, CAN J DIABE IN PRESS